Bingshi Guo

This inventor holds 18 USPTO granted patents and 15 published patent applications, plus 8 CIPO patents and 5 EPO patents. Top assignees: I-Mab Biopharma US Limited, I-Mab, I-Mab Biopharma (Hangzhou) Co., Ltd.. Active years: 2018-2026.

USPTO Granted Patents = 18 (Patent Applications = 15)

% Patents Active = 94.4

CIPO Patents = 8 (Patent Applications = 10)

EPO Patents = 5 (Patent Applications = 24)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

10 out of 14

I-Mab Biopharma US Limited

I-Mab Biopharma (Hangzhou) Co., Ltd.

patents

4. 2 out of 2

I-Mab Biopharma Co., Ltd.

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577313 - ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF (2026-03-17),

2. 12091467 - CD47 monoclonal antibodies and uses thereof (2024-09-17),

3. 11926662 - Anti-GM-CSF antibodies and uses thereof (2024-03-12),

4. 11613577 - Anti-CD73 antibodies and uses thereof (2023-03-28),

5. 11414485 - Anti-LAG-3 antibodies and uses thereof (2022-08-16),

6. 11401331 - Anti-PD-L1 antibody and IL-7 fusions (2022-08-02),

7. 11261259 - Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof (2022-03-01),

8. 11220546 - Anti-PD-L1 antibodies and uses thereof (2022-01-11),

9. 11208486 - Human PD-L1 antibodies (2021-12-28),

10. 11034771 - Anti-CD73 anti-PD-L1 bispecific antibodies (2021-06-15),

11. 10973853 - Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof (2021-04-13),

12. 10889641 - Anti-GM-CSF antibodies and uses thereof (2021-01-12),

13. 10723799 - Anti-PD-L1 antibodies and uses thereof (2020-07-28),

14. 10647767 - Anti-GM-CSF antibodies and uses thereof (2020-05-12),

15. 10584169 - Anti-CD73 antibodies and uses thereof (2020-03-10),

Title: Bingshi Guo: Innovator in Monoclonal Antibodies

Introduction

Bingshi Guo is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 18 patents to his name, Guo's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents are innovative developments in CD47 monoclonal antibodies and their uses. This invention provides novel CD47 antibodies or immunologically active fragments that exhibit low immunogenicity in humans. These antibodies are designed to minimize red blood cell depletion or hemagglutination, along with pharmaceutical compositions that can be utilized for treating diseases mediated by CD47 or inhibiting phagocytosis and platelet aggregation. Another significant patent involves anti-GM-CSF antibodies and their applications. This patent includes humanized antibodies and fragments, which are intended for therapeutic, diagnostic, and prognostic purposes, particularly in treating inflammatory and autoimmune diseases.

Career Highlights

Bingshi Guo has worked with notable companies in the biotechnology sector, including I-Mab Biopharma US Limited and I-Mab. His experience in these organizations has allowed him to advance his research and contribute to the development of groundbreaking therapies.

Collaborations

Guo has collaborated with esteemed colleagues such as Lei Fang and Zhengyi Wang. These partnerships have fostered an environment of innovation and have been instrumental in the success of his projects.

Conclusion

Bingshi Guo's contributions to the field of monoclonal antibodies exemplify his dedication to advancing medical science. His innovative patents and collaborations highlight his role as a key figure in biotechnology.